Literature DB >> 8453104

Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion.

J Anastasi1, J Feng, M M Le Beau, R A Larson, J D Rowley, J W Vardiman.   

Abstract

Clonality in myelodysplastic syndromes (MDS) has been studied with various techniques including glucose-6-phosphate dehydrogenase (G6PD) isoenzyme and cytogenetic analyses, and with molecular techniques such as gene deletion studies and the analysis of restriction fragment-length polymorphisms (RFLP) of X-linked genes. In this study, we investigated the use of fluorescence in situ hybridization (FISH) with a chromosome-specific probe to examine cytogenetic clonality in peripheral blood (PB) cells from three patients with MDS. In each case, trisomy 8 was shown by conventional cytogenetic analysis at the time of the initial diagnosis. By using FISH with a probe for the centromere of chromosome 8, we identified the trisomy in individual PB cells from Wright-stained smears. With this technique, we could determine the cell lineage involved by the trisomy, and through serial analyses we could assess the response of the clonal and nonclonal cells to growth-factor therapy, and the expansion of the trisomic clone over time. In each of the three cases, various proportions of granulocytes, monocytes, eosinophils, and basophils showed trisomy 8 by FISH analysis. In none of the cases did we detect trisomy 8 in lymphocytes. By analysis of PB cells before and during therapy with recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF), we found that GM-CSF stimulated both trisomic and disomic cells. During a 1-year period of sequential study, we detected an abrupt increase in the percentage of trisomic cells in one patient, a stable percentage in another, and a slowly increasing percentage in the third. The abrupt increase in the first patient preceded a transformation to a more acute phase by 2 months. We conclude that FISH analysis of PB cells of patients with MDS offers an additional approach to the study of clonality in this disorder. In some cases this analysis may provide a useful and simple means of assessing response to therapy and progression of disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8453104

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

Review 1.  The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes.

Authors:  Azra Raza; Naomi Galili
Journal:  Nat Rev Cancer       Date:  2012-12       Impact factor: 60.716

2.  BCOR regulates myeloid cell proliferation and differentiation.

Authors:  Q Cao; M D Gearhart; S Gery; S Shojaee; H Yang; H Sun; D-C Lin; J-W Bai; M Mead; Z Zhao; Q Chen; W-W Chien; S Alkan; T Alpermann; T Haferlach; M Müschen; V J Bardwell; H P Koeffler
Journal:  Leukemia       Date:  2016-02-05       Impact factor: 11.528

3.  Cytogenetic findings in 179 patients with myelodysplastic syndromes.

Authors:  D Haase; C Fonatsch; M Freund; B Wörmann; H Bodenstein; H Bartels; B Stollmann-Gibbels; E Lengfelder
Journal:  Ann Hematol       Date:  1995-04       Impact factor: 3.673

4.  Trisomy 8, a Cytogenetic Abnormality in Myelodysplastic Syndromes, Is Constitutional or Not?

Authors:  Sílvia Saumell; Francesc Solé; Leonor Arenillas; Julia Montoro; David Valcárcel; Carme Pedro; Carmen Sanzo; Elisa Luño; Teresa Giménez; Montserrat Arnan; Helena Pomares; Raquel De Paz; Beatriz Arrizabalaga; Andrés Jerez; Ana B Martínez; Judith Sánchez-Castro; Juan D Rodríguez-Gambarte; José M Raya; Eduardo Ríos; María Rodríguez-Rivera; Blanca Espinet; Lourdes Florensa
Journal:  PLoS One       Date:  2015-06-12       Impact factor: 3.240

Review 5.  The Genomics of Myelodysplastic Syndromes: Origins of Disease Evolution, Biological Pathways, and Prognostic Implications.

Authors:  Hassan Awada; Bicky Thapa; Valeria Visconte
Journal:  Cells       Date:  2020-11-20       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.